L'archivio delle pubblicazioni di Fondazione ICONA

2019

L Shepherd, L Ryom, M Law, K Petoumenos, CI Hatleberg, A d'Arminio Monforte, C Sabin, M Bower, F Bonnet, P Reiss, S de Wit, C Pradier, R Weber, W El-Sadr, J Lundgren, A Mocroft; Data Collectionon Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. Clin Infect Dis. 2019 Feb 1;68(4):650-657. doi: 10.1093/cid/ciy508.

2018

Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d’Arminio Monforte A, Kovari H, Law, M, Lundgren JD, Sabin C, On behalf of the Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group. Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study. Journal of the International AIDS Society 2018
Sabin CA, Ryom L, d'Arminio Monforte A, Hatleberg CI, Pradier C, El-Sadr W, Kirk O, Weber R, Phillips AN, Mocroft A, Bonnet F, Law M, de Wit S, Reiss P, Lundgren JD; D:A:D Study Group. Abacavir use and risk of recurrent myocardial infarction. AIDS. 2018; 32(1):79-88.
L Ryom, JD Lundgren, W El-Sadr, P Reiss, O Kirk, M Law, A Phillips, R Weber, E Fontas, A d’ Arminio Monforte, S de Wit, F Dabis, CI Hatleberg, C Sabin, A Mocroft. On behalf of the D:A:D Study group. Association between Cardiovascular Disease & Use of Contemporary Protease Inhibitors: The D:A:D Study. Lancet HIV 2018.
CI HatlebergI, L Ryom, A d'Arminio Monforte, E Fontas, P Reiss, O Kirk, W El-Sadr, A Phillips, S de Wit, F Dabis, R Weber, M Law, JD Lundgren, C Sabin; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV-positive persons: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. HIV Med. 2018 Oct;19(9):605-618. doi: 10.1111/hiv.12639. Epub 2018 Jul 18.

2017

MA Boyd, A Mocroft, L Ryom, AD Monforte, C Sabin , WM El-Sadr, CI Hatleberg, S De Wit, R Weber, E Fontas, A Phillips, F Bonnet, P Reiss, J Lundgren, M Law. Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study. PLoS Med. 2017;14(11):e1002424
L Ryom, A Mocroft, O Kirk, P Reiss, M Ross, C Smith, O Moranne, P Morlat, CA Fux; C Sabin, A Phillips, M Law, JD Lundgren. On behalf of the D:A:D Study group. Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals. AIDS. 2017; 31(9):1261-1270.
L Shepherd, L Ryom, M Law, C Ingrid Hatleberg, S de Wit, A d'Arminio Monforte, M Battegay, A Phillips, F Bonnet, P Reiss, C Pradier, A Grulich, C Sabin, J Lundgren, A Mocroft. Differences in virological and immunological risk factors for non-Hodgkin and Hodgkin lymphoma. J Natl Cancer Inst. 2017

2016

CA Sabin, P. Reiss, L Ryom, AN Phillips, R Weber, M Law, E Fontas, A Mocroft, S de Wit, C Smith, F Dabis, A d’Arminio Monforte, W El-Sadr, J D Lundgren for the D:A:D Study Group. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. BMC Medicine 2016 14:61 DOI: 10.1186/s12916-016-0588-4.
A Mocroft, JD Lundgren, M Ross, CA Fux P Reiss, O Moranne, P Morlat, A d'Arminio Monforte, O Kirk, L Ryom, on behalf of The Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 2016 Jan; 3(1):e23-32.
L Ryom, JD Lundgren, S De Wit, H Kovari, P Reiss, M Law, W El-Sadr, A D’Arminio Monforte, Amanda Mocroft, C Smith, E Fontas, F Dabis, A Phillips and C Sabin for the D:A:D Study Group. Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. AIDS. 2016 Jul 17;30(11):1731-43
DC Boettiger, CA Sabin, A Grulich, L Ryom, F Bonnet, P Reiss, A d’ArminioMonforte, O Kirk, A Phillips, M Bower, G Fätkenheuer, JD Lundgren, M Law on behalf of the Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group. Is Nelfinavir Exposure Associated with Cancer Incidence in HIV-positive individuals? AIDS. 2016 Jun 19;30(10):1629-37.
5. CI Hatleberg, L Ryom, W El-Sadr, C Smith, R Weber, P Reiss, E Fontas, F Dabis, M Law, A d’Arminio Monforte, Stephane De Wit, A Mocroft, A Phillips, J D. Lundgren and C Sabin for the D:A:D Study Group. Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals AIDS. 2016 Jun 19; 30(10):1583-96.
Amit C Achhra; Amanda Mocroft; Peter Reiss; Caroline Sabin; Lene Ryom; Stephane de Wit; Colette J Smith; Antonella d´arminio Monforte; Andrew Phillips; Rainer Weber; Jens Lundgren; Matthew G Law; The D:A:D Study Group. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Med. 2016 Apr;17(4):255-68.
N Friis-Møller, L Ryom, C Smith, R Weber, P Reiss, F Dabis, S De Wit, A D’Arminio Monforte, O Kirk, E Fontas, C Sabin, A Phillips, J Lundgren, M Law, on behalf of the D:A:D study group. An updated prediction model of the global risk of cardiovascular disease in HIV- positive persons. European Journal of Eur J Prev Cardiol. 2016 Jan;23(2):214-23
DA Kamara, CA Sabin, L Ryom, P Reiss, M Rickenbach, CJ Smith, A Phillips, A Mocroft, S De Wit, M Law, A d’Arminio Monforte, F Dabis, C Pradier, JD Lundgren. Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study. Antivir Ther. 2016; 21(6):495-506.
L Ryom, JD Lundgren, M Ross, O Kirk, M Law, P Morlat, C Smit, E Fontas, CA Fux, CI Hatleberg, S de Wit, CA Sabin and A Mocroft for the D:A:D Study Group. Renal Impairment and Cardiovascular Disease in HIV-positive Individuals; The D:A:D Study. J Infect Dis. 2016 Oct 15;214(8)

2015

M Bruyand, L Ryom, L Shepherd, G Fatkenheuer, A Grulich, P Reiss, S de Wit, A d ‘Arminio Monforte, H Furrer, C Pradier, J Lundgren, C Sabin; D:A:D study group. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study. J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):568-577.
N Friis-Møller, L Ryom, C Smith, R Weber, P Reiss, F Dabis, S De Wit, A d’Arminio Monforte, O Kirk, E Fontas, C Sabin, A Phillips, J Lundgren, M Law, on behalf of the D:A:D study group. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons. Eur J Prev Cardiol. 2015 Apr 16. pii: 2047487315579291
A Mocroft, JD Lundgren, M Ross, M Law, P Reiss, O Kirk, C Smith, D Wentworth, J Neuhaus, CA Fux, O Moranne, P Morlat, MA Johnson, L Ryom on behalf of the Data on Adverse Events (D:A:D) study group, the Royal Free Hospital Clinic Cohort and the INSIGHT, SMART and ESPRIT study group. Development and validation of a risk-score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PlOS Medicine 2015 Mar 31; 12 (3)

2014

K Petoumenos, P Reiss, L Ryom, M Rickenbach, C Sabin, W El-Sadr, A d'Arminio Monforte, A Phillips, S De Wit, O Kirk, F Dabis, C Pradier, J Lundgren, M Law; D:A:D Study Group. Increased risk of cardiovascular disease (CVD) with age in HIV positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations. HIV Med. 2014 Nov;15(10):595-603. abstract
L Ryom, A Mocroft, O Kirk, M Ross, P Reiss, CA Fux, P Morlat, O Moranne, C Smith, W El-Sadr, M Law, JD Lundgren et al. for the D:A:D study group. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons in the D:A:D study. AIDS. 2014 Jan 14;28(2):187-99
DA Kamara, L Ryom, M Ross, O Kirk, P Reiss, P Morlat, O Moranne, CA Fux, A Mocroft, C Sabin, JD Lundgren, CJ Smith. . Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study BMC Nephrol. 2014 Mar 25;15:51. doi: 10.1186/1471-2369-15-51.
CJ Smith, L Ryom, R Weber, P Morlat, C Pradier, P Reiss, JD Kowalska, S De Wit, M Law, W el Sadr, O Kirk, N Friis-Moller, A d’Arminio Monforte, AN Phillips, C Sabin, JD Lundgren, D:A:D Study Group. Trends in underlying causes of death in poeple with HIV from 1999-2011 (D:A:D): a multicohort collaboration. Lancet. 2014 jul 19:384(9939):241-8. doi: 10.1016/S0140-6736(14)60604-8

2013

CA Sabin, L Ryom, S De Wit, A Mocroft, AN Phillips, SW Worm, R Weber, A d’Arminio Monforte, P Reiss, D Kamara, W El-Sadr, C Pradier, F Dabis, M Law, J Lundgren. Associations between immune depression and cardiovascular events in HIV infection. AIDS. 13 November 2013; Volume 27; Issue 17; 2735-2748
SW Worm, M Bower, P Reiss, F Bonnet, M Law, G Fätkenheuer, A d'Arminio Monforte, DI Abrams, A Grulich, E Fontas, O Kirk, H Furrer, S De Wit, A Phillips, JD Lundgren, CA Sabin. Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. BMC Infect Dis. 2013 Oct 9;13(1):471
H Kovari, C Sabin, B Ledergerber, L Ryom, SW Worm, C Smith, A Phillips, P Reiss, E Fontas, K Petoumenos, S De Wit, P Morlat, JD Lundgren, R Weber. Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study. Clin Infect Dis. 2013 Mar;56(6):870-9.
C Sabin, L Ryom, H Kovari, O Kirk, S de Wit, M Law, P Reiss, F Dabis, C Pradier, W El Sadr, A d’Arminio Monforte, D Kamara, AN Phillips, JD Lundgren JD. Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: The D: A: D Study. J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):456-63.
d'Arminio Monforte A, P Reiss, L Ryom, W El-Sadr, F Dabis, S De Wit, SW Worm, MG Law, R Weber, O Kirk, C Pradier, AN Phillips, JD Lundgren, CA Sabin. Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. AIDS 2013 Jan 28;27(3):407-15.

2012

K Petoumenos, SW Worm, E Fontas, R Weber, S De Wit, M Bruyand, P Reiss, W El-Sadr, A d'Arminio Monforte, N Friis-Møller, JD Lundgren, MG Law, On behalf of the D:A:D Study Group. Predicting the short term risk of diabetes in HIV positive patients: The Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study. J Int AIDS Soc. 2012 Oct 10;15(2):17426.
SW Worm, DA Kamara, P Reiss, E Fontas, S De Wit, W El-Sadr, Ad'Arminio Monforte, M Law, A Phillips, L Ryom, F Dabis, R Weber, C Sabin, JD Lundgren on behalf of the D:A:D Study Group. Evaluation of HIV protease inhibitor usage and the risk of sudden death or non-haemorrhagic stroke. JID 2012 Feb;205(4):535-9

2011

DA Kamara, SW Worm, P Reiss, M Rickenbach, A Phillips, O Kirk, A d'Arminio Monforte, M Bruyand, M Law, S De Wit, C Smith, C Pradier, JD Lundgren, C Sabin. The impact of fasting on the interpretation of triglyceride levels for predicting myocardial infarction risk in HIV-positive individuals: The D:A:D Study. J Infect Dis. 2011 Aug;204(4):521-525.
JD Kowalska, N Friis-Møller, O Kirk, W Bannister, A Mocroft, C Sabin, P Reiss, J Gill, C Lewden, A Phillips, A d'Arminio Monforte, M Law, J Sterne, S De Wit, JD Lundgren; CoDe Working Group; D:A:D Study Group. The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology. 2011 Jul;22(4):516-23
SW Worm, DA Kamara, P Reiss, O Kirk , W El-Sadr, C Fux, E Fontas, A Phillips, A d'Arminio Monforte, S De Wit, K Petoumenos, N Friis-Mller, P Mercie, JD Lundgren, C Sabin. Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. AIDS. 2011 Jul 31;25(12):1497-504
K Petoumenos, S Worm, P Reiss, S de Wit, A d'Arminio Monforte, C Sabin, N Friis-Møller, R Weber, P Mercie, C Pradier, W El-Sadr, O Kirk, J Lundgren, M Law; for the D:A:D Study Group. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study. HIV Med. 2011 Aug;12(7):412-21

2010

R Weber, C Sabin, P Reiss, S de Wit, SW Worm, M Law, F Dabis, A d'Arminio Monforte, E Fontas, W El-Sadr, O Kirk, M Rickenbach, A Phillips, B Ledergerber, J Lundgren. HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. Antivir Ther. 2010;15(8):1077-86
C Smith, SW Worm, N Friis-Møller, CA Sabin, A Sjøl, JD Lundrgen, R Salbøl-Brandt, M Rickenbach, P Pezzotti, E Krum, L Gras, E Balestre, A Sundström, M Delforge, E Fontas, F Torres, K Petoumenos, J Kjær, S Collins, S Storpher, G Pearce, R Rode, I Weller. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. AIDS. 2010 Jun 19;24(10):1537-48
N Friis-Møller, R Thiébaut, P Reiss, R Weber, AD Monforte, S De Wit, W El-Sadr, E Fontas, S Worm, O Kirk, A Phillips, CA Sabin, JD Lundgren, MG Law; DAD study group. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):491-501
SW Worm, S Sabin, R Weber, P Reiss, W El-Sadr, F Dabis, S De Wit, M Law, A d'Arminio Monforte, N Friis-Møller, E Fontas, I Weller, A Phillips, J Lundgren. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010 Feb 1;201(3):318-30
SW Worm, N Friis-Møller, M Bruyand, A d'Arminio Monforte, M Rickenbach, P Reiss, W El-Sadr, A Phillips, J Lundgren, C Sabin; for the D:A:D study group. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS 2010 Jan 28;24(3):427-35

2009

SW Worm, S De Wit, R Weber, CA Sabin, P Reiss, W El-Sadr, AD Monforte, O Kirk, E Fontas, F Dabis, MG Law, JD Lundgren, N Friis-Møller. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the DATA Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). Circulation. 2009 Feb 17;119(6):805-11
SW Worm, CA Sabin, P Reiss, W El-Sadr, AD Monforte, C Pradier, R Thiebaut, M Law, M Rickenback, S De Wit, JD Lundgren, NF Møller Presence of the metabolic syndrome (MS) is not a better predictor of cardiovascular disease (CVD) than the sum of its components in HIV-infected individuals. Data Collection on Adverse Events of Anti-HIV Drugs (The D:A:D study). Diabetes Care. 2009 Mar;32(3):474-80

2008

A d'Arminio Monforte, D Abrams, C Pradier, R Weber, P Reiss, F Bonnet, O Kirk, M Law, S De Wit, N Friis-Møller, AN Phillips, CA Sabin, JD Lundgren; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS. 2008 Oct 18;22(16):2143-53
Data Collection on Adverse Events of Anti-HIV Drugs Study Group, CA Sabin, A d'Arminio Monforte, N Friis-Moller, R Weber, WM El-Sadr, P Reiss, O Kirk, P Mercie, MG Law, S De Wit, C Pradier, AN Phillips, JD Lundgren. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clin Infect Dis. 2008 Apr 1;46(7):1101-10
The D:A:D: Study Group- Writing group: CA Sabin, SW Worm, R Weber, P Reiss, W El Sadr, F Dabis, S De Wit, M Law, A d'Arminio Monforte, N Friis-Møller, O Kirk, C Pradier, I Weller, AN Phillips, JD Lundgren. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008 371 (9622): 1417-26
S de Wit, CA Sabin, R Weber, SW Worm, P Reiss, C Cazanave, W El-Sadr, A d´Arminio Monforte, E Fontas, MG Law, N Friis-Møller, JD Lundgren. Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: the D:A:D study. Diabetes Care. 2008 Jun;31(6):1224-9

2007

The D:A:D: Study Group- Writing committee: N Friis-Møller, P Reiss, CA Sabin, R Weber, A d'Arminio Monforte, WM. El-Sadr, R Thiébaut, S De Wit, O Kirk, E Fontas, MG Law, AN Phillips, and JD Lundgren. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-35

2006

MG Law, N Friis-Møller, WM El-Sadr, R Weber, P Reiss, A d'Arminio Monforte, R Thiébaut, L Morfeldt, S De Wit, C Pradier, G Calvo, O Kirk, CA Sabin, AN Phillips, and JD Lundgren for the D:A:D Study Group. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study.. HIV Med. 2006; 7:218-230.
D:A:D: Study- Writing committee: R Weber, CA Sabin, N Friis-Møller, P Reiss, WM. El-Sadr, O Kirk, F Dabis, MG Law, C Pradier, S De Wit, B Åkerlund, G Calvo, A d'Arminio Monforte, M Rickenbach, B Ledergerber, AN Phillips, and JD Lundgren. Liver-related deaths among persons infected with the human immunodeficiency virus: The D:A:D Study. Arch Intern Med. 2006;166:1632-164.
M Puoti, A Cozzi-Lepri, C Arici C, NF Moller, JD Lundgren, B Ledergerber, M Rickenbach, I Suarez-Lozano, M Garrido, F Dabis, M Winnock, L Milazzo, A Gervais, F Raffi, J Gill, J Rockstroh, N Ourishi, C Mussini, A Castagna, A De Luca, A d’Arminio Monforte; HBV-HIV International Intercohort Study Group. Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. Antivir Ther. 2006;11(5):567-74

2005

R Thiébaut, W El-Sadr, N Friis-Moller, M Rickenbach, P Reiss, A d'Arminio Monforte, L Morfeldt, E Fontas, O Kirk, S De Wit, G Calvo, MG Law, F Dabis, CA Sabin, JD Lundgren, for the D :A :D : Study Group Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther 2005; 10(7) :811-23.

2004

E Fontas, F van Leth, CA Sabin, N Friis-Møller, M Rickenbach, A d'Arminio Monforte, O Kirk, M Dupon, L Morfeldt, S Mateu, K Petoumenos, W El-Sadr, S de Wit, JD Lundgren, C Pradier, P Reiss. Lipid profiles in HIV-1 infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189: 1056-1075
A d'Arminio Monforte, CA Sabin, AN Phillips, P Reiss, R Weber, O Kirk, W El-Sadr, S De Wit, S Mateu, K Petoumenos, F Dabis, C Pradier, L Morfeldt, JD Lundgren, N Friis-Møller, WRITING Commettee of the D :A :D : Study Group. Cardio- and cerebrovascular events in HIV-infected persons. AIDS. 2004;18(13):1811-7

2003

M Law, N Friis-Moller, R Weber, P Reiss, R Thiebaut, O Kirk, A d'Arminio Monforte, C Pradier, L Morfeldt, G Calvo, W El-Sadr, S De Wit, CA Sabin, JD Lundgren; DAD Study Group. Modelling the three year risk of myocardial infarction among participants in the D:A:D study. HIV Medicine 2003; 4(1):1-10.
N. Friis-Møller, R Weber, P Reiss, R Thiebaut, O Kirk, A d'Arminio Monforte, C Pradier, L Morfeldt, G Clavo, M Law, W El-Sadr, S De Witt, C Sabin, AN Phillips, J Lundgren for the D:A:D Study Group. Cardiovascular risk factors in HIV patients - association with antiretroviral therapy Results from the DAD Study. AIDS 2003; 17(8):1179-1193.
The D:A:D Study Group. Combination antiretroviral therapy and risk of myocardial infarction. The Data Collection Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. N Engl J Med 2003; 349:1993-2003.

Publications

La raccolta di tutte le pubblicazioni di Fondazione ICONA,...

D:A:D